Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 5/20 | 0.60 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.60 |
| ▸ | CNR2 | P34972 | 4/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037471 | 1.00 | CACNA1H (0.60) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL3042543 | 0.87 | CACNA1I (0.60) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL1066005 | 0.82 | CACNA1I (0.67) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL17451429 | 0.82 | CACNA1I (0.67) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL1064504 | 0.81 | CACNA1I (0.65) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL1062854 | 0.80 | CACNA1I (0.75) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL3041292 | 0.79 | CACNA1I (0.76) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL3036757 | 0.79 | CACNA1I (0.76) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL1063192 | 0.78 | CACNA1I (0.78) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 | |
| SCHEMBL4501672 | 0.77 | CACNA1I (0.73) | CACNA1HCACNA1ICNR2CACNA1GKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | claimed |
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | disclosed |
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | disclosed |
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | disclosed |
| WO-2009054982-A1 | PYRAZINYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CNR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.